Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446485
Status:
COMPLETED
Last Update Posted:
2015-09-28
First Post:
2007-03-12
Brief Title:
Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency
Sponsor:
Milsing doo
Organization:
Milsing doo
Study Overview
Official Title:
Efficacy and Safety of Ginkgo Biloba Standardized Extract 24 Ginkoflavonoglicozides and 6 Terpenes in Treatment of Mild Cognitive and Concentration Impairment
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine weather Ginkgo biloba standardized extract 24 ginkoflavonoglicozides and 6 terpenes is effective in treatment of cognitive and concentration impairment
Detailed Description:
Inclusion criteria is cerebrovascular insufficiency MNSE20 90 patients are divided into three groups randomly First group is being administered 120 mg ginkgo biloba extract second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months Methods used for evaluation are SCAG MMSE MDRS VFT CGI TCD and color Doppler of carotid arteries Methods used for follow up safety include routine blood tests biochemical tests neurologic and physical examination vital signs and ECG
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None